메뉴 건너뛰기




Volumn 75, Issue 4, 2008, Pages 305-310

What role will 'gliptins' play in glycemic control?

Author keywords

[No Author keywords available]

Indexed keywords


EID: 45849087724     PISSN: 08911150     EISSN: None     Source Type: Journal    
DOI: 10.3949/ccjm.75.4.305     Document Type: Review
Times cited : (11)

References (36)
  • 1
    • 34250772381 scopus 로고    scopus 로고
    • Last accessed February 28, 2008
    • National Diabetes Surveillance System. www.cdc.gov/diabetes/ statistics/prev/national/figpersons.htm. Last accessed February 28, 2008.
    • National Diabetes Surveillance System
  • 3
    • 33845996154 scopus 로고    scopus 로고
    • Standards of medical care in diabetes - 2007
    • American Diabetes Association
    • American Diabetes Association. Standards of medical care in diabetes - 2007. Diabetes Care 2007; 30(suppl 1):S4-S41.
    • (2007) Diabetes Care , vol.30 , Issue.SUPPL. 1
  • 4
    • 0347133334 scopus 로고    scopus 로고
    • Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes
    • Saydah SH, Fradkin J, Cowie CC. Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes. JAMA 2004; 291:335-342.
    • (2004) JAMA , vol.291 , pp. 335-342
    • Saydah, S.H.1    Fradkin, J.2    Cowie, C.C.3
  • 5
    • 3042714557 scopus 로고    scopus 로고
    • The burden of treatment failure in type 2 diabetes
    • Brown JB, Nichols GA, Perry A. The burden of treatment failure in type 2 diabetes. Diabetes Care 2004, 27:1535-1540.
    • (2004) Diabetes Care , vol.27 , pp. 1535-1540
    • Brown, J.B.1    Nichols, G.A.2    Perry, A.3
  • 6
    • 33845340507 scopus 로고    scopus 로고
    • Lower baseline glycemia reduces apparent oral agent glucose-lowering efficacy: A meta-regression analysis
    • Bloomgarden ZT, Dodis R, Viscoli CM, Holmboe ES, Inzucchi SE. Lower baseline glycemia reduces apparent oral agent glucose-lowering efficacy: a meta-regression analysis. Diabetes Care 2006; 29:2137-2139.
    • (2006) Diabetes Care , vol.29 , pp. 2137-2139
    • Bloomgarden, Z.T.1    Dodis, R.2    Viscoli, C.M.3    Holmboe, E.S.4    Inzucchi, S.E.5
  • 7
    • 0022617246 scopus 로고
    • Reduced incretin effect in type 2 (non-insulin-dependent) diabetes
    • Nauck M, Stockmann F, Ebert R, Creutzfeldt W. Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. Diabetologia 1986; 29:46-52.
    • (1986) Diabetologia , vol.29 , pp. 46-52
    • Nauck, M.1    Stockmann, F.2    Ebert, R.3    Creutzfeldt, W.4
  • 8
    • 0141446228 scopus 로고    scopus 로고
    • Enhancing incretin action for the treatment of type 2 diabetes
    • Drucker DJ. Enhancing incretin action for the treatment of type 2 diabetes. Diabetes Care 2003; 26:2929-2940.
    • (2003) Diabetes Care , vol.26 , pp. 2929-2940
    • Drucker, D.J.1
  • 9
    • 33845408977 scopus 로고    scopus 로고
    • Gut hormones and related concepts
    • Bloomgarden ZT. Gut hormones and related concepts. Diabetes Care 2006; 29:2319-2324.
    • (2006) Diabetes Care , vol.29 , pp. 2319-2324
    • Bloomgarden, Z.T.1
  • 10
    • 0027248866 scopus 로고
    • Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients
    • Nauck MA, Kleine N, Orskov C, et al. Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients. Diabetologia 1993; 36:741-744.
    • (1993) Diabetologia , vol.36 , pp. 741-744
    • Nauck, M.A.1    Kleine, N.2    Orskov, C.3
  • 11
    • 18144401971 scopus 로고    scopus 로고
    • Effects of exenatide (exendin-A) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes
    • DeFronzo RA, Ratner RE, Han J, Kim DD, Fineman MS, Baron AD. Effects of exenatide (exendin-A) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 2005; 28:1092-1100.
    • (2005) Diabetes Care , vol.28 , pp. 1092-1100
    • DeFronzo, R.A.1    Ratner, R.E.2    Han, J.3    Kim, D.D.4    Fineman, M.S.5    Baron, A.D.6
  • 12
    • 0028803336 scopus 로고
    • Both subcutaneously and intravenously administered glucagon-like peptide I are rapidly degraded from the NH2-terminus in type II diabetic patients and in healthy subjects
    • Deacon CF, Nauck MA, Toft-Nielsen M, Pridal L, Willms B, Holst JJ. Both subcutaneously and intravenously administered glucagon-like peptide I are rapidly degraded from the NH2-terminus in type II diabetic patients and in healthy subjects. Diabetes 1995; 44:1126-1131.
    • (1995) Diabetes , vol.44 , pp. 1126-1131
    • Deacon, C.F.1    Nauck, M.A.2    Toft-Nielsen, M.3    Pridal, L.4    Willms, B.5    Holst, J.J.6
  • 13
    • 17844399596 scopus 로고    scopus 로고
    • Glucagon-like peptide-1 mediates the therapeutic actions of DPP-4 inhibitors
    • Holst JJ, Deacon CF. Glucagon-like peptide-1 mediates the therapeutic actions of DPP-4 inhibitors. Diabetologia 2005; 48:612-615.
    • (2005) Diabetologia , vol.48 , pp. 612-615
    • Holst, J.J.1    Deacon, C.F.2
  • 14
    • 0033303516 scopus 로고    scopus 로고
    • Glucagon-like peptide-1-(7-36) amide is transformed to glucagon-like peptide-1-(9-36)amide by dipeptidyl peptidase IV in the capillaries supplying the L cells of the porcine intestine
    • Hansen L, Deacon CF, Orskov C, Holst JJ. Glucagon-like peptide-1-(7-36) amide is transformed to glucagon-like peptide-1-(9-36)amide by dipeptidyl peptidase IV in the capillaries supplying the L cells of the porcine intestine. Endocrinology 1999; 140:5356-5363.
    • (1999) Endocrinology , vol.140 , pp. 5356-5363
    • Hansen, L.1    Deacon, C.F.2    Orskov, C.3    Holst, J.J.4
  • 15
    • 33847072735 scopus 로고    scopus 로고
    • Raun K, von Voss P, Gotfredsen CF, Golozoubova V, Rolin B, Knudsen LB. Liraglutide, a long-acting glucagen-like peptide-1 analog, reduces body weight and food intake in obese candy-fed rats, whereas a dipeptidyl pieptidase-IV inhibitor, vildagliptin, does not. Diabetes 2007; 56:8-15.
    • Raun K, von Voss P, Gotfredsen CF, Golozoubova V, Rolin B, Knudsen LB. Liraglutide, a long-acting glucagen-like peptide-1 analog, reduces body weight and food intake in obese candy-fed rats, whereas a dipeptidyl pieptidase-IV inhibitor, vildagliptin, does not. Diabetes 2007; 56:8-15.
  • 16
    • 33748331194 scopus 로고    scopus 로고
    • Chronic-inhibition of dipeptidyl peptidase IV with a sitagliptin analog preserves pancreatic beta-cell mass and function in a rodent model of type 2 diabetes
    • Mu J, Woods J, Zhou YP, et al. Chronic-inhibition of dipeptidyl peptidase IV with a sitagliptin analog preserves pancreatic beta-cell mass and function in a rodent model of type 2 diabetes. Diabetes 2006; 55:1695-1704.
    • (2006) Diabetes , vol.55 , pp. 1695-1704
    • Mu, J.1    Woods, J.2    Zhou, Y.P.3
  • 17
    • 0037342614 scopus 로고    scopus 로고
    • Dipeptidyl peptidase IV inhibitor treatment stimulates beta-cell survival and islet neogenesis in streptozotocin-Induced diabetic rats
    • Pospisilik JA, Martin J, Doty T, et al. Dipeptidyl peptidase IV inhibitor treatment stimulates beta-cell survival and islet neogenesis in streptozotocin-Induced diabetic rats. Diabetes 2003; 52:741-750.
    • (2003) Diabetes , vol.52 , pp. 741-750
    • Pospisilik, J.A.1    Martin, J.2    Doty, T.3
  • 18
    • 33749871472 scopus 로고    scopus 로고
    • Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabites
    • Herman GA, Bergman A, Stevens C, et al. Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabites. J Clin Endocrinol Metab 2006; 91:4612-4619.
    • (2006) J Clin Endocrinol Metab , vol.91 , pp. 4612-4619
    • Herman, G.A.1    Bergman, A.2    Stevens, C.3
  • 19
    • 33845472504 scopus 로고    scopus 로고
    • Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes
    • Aschner P, Kipnes MS, Lunceford JK, Sanchez M, Mickel C, Williams-Herman DE. Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care 2006; 29:2632-2637.
    • (2006) Diabetes Care , vol.29 , pp. 2632-2637
    • Aschner, P.1    Kipnes, M.S.2    Lunceford, J.K.3    Sanchez, M.4    Mickel, C.5    Williams-Herman, D.E.6
  • 20
    • 33845489598 scopus 로고    scopus 로고
    • Raz I, Hanefeld M, Xu L, Caria C, Williams-Herman D. Khatami H. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus. Diabetologia 2006; 49:2564-2571.
    • Raz I, Hanefeld M, Xu L, Caria C, Williams-Herman D. Khatami H. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus. Diabetologia 2006; 49:2564-2571.
  • 21
    • 33846796143 scopus 로고    scopus 로고
    • Effect of adding sitagliptin, a dipeptidyl peptidase-4 inhibitor, to metformin on 24-h glycaemic control and beta-cell function in patients with type 2 diabetes
    • Brazg R, Xu L, Dalla Man C, Cobelli C, Thomas K, Stein PP. Effect of adding sitagliptin, a dipeptidyl peptidase-4 inhibitor, to metformin on 24-h glycaemic control and beta-cell function in patients with type 2 diabetes. Diabetes Obes Metab 2007; 9:186-193.
    • (2007) Diabetes Obes Metab , vol.9 , pp. 186-193
    • Brazg, R.1    Xu, L.2    Dalla Man, C.3    Cobelli, C.4    Thomas, K.5    Stein, P.P.6
  • 22
    • 33845476757 scopus 로고    scopus 로고
    • Efficacy and safety of the clipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone
    • Charbonnel B, Karasik A, Liu J, Wu M, Meininger G. Efficacy and safety of the clipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. Diabetes Care 2006; 29:2638-2643.
    • (2006) Diabetes Care , vol.29 , pp. 2638-2643
    • Charbonnel, B.1    Karasik, A.2    Liu, J.3    Wu, M.4    Meininger, G.5
  • 23
    • 33751557143 scopus 로고    scopus 로고
    • Rosenstock J, Brazg R, Andryuk PJ, Lu K, Stein P; Sitagliptin Study 019 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, Placebo-controlled, parallel-group study. Clin Ther 2006; 28:1556-1568.
    • Rosenstock J, Brazg R, Andryuk PJ, Lu K, Stein P; Sitagliptin Study 019 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, Placebo-controlled, parallel-group study. Clin Ther 2006; 28:1556-1568.
  • 24
    • 33847024333 scopus 로고    scopus 로고
    • Efficacy and tolerability of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy over 12 weeks in patients with type 2 diabetes
    • Scott R, Wu M, Sanchez M, Stein P. Efficacy and tolerability of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy over 12 weeks in patients with type 2 diabetes. Int J Clin Pract 2007; 61:171-180.
    • (2007) Int J Clin Pract , vol.61 , pp. 171-180
    • Scott, R.1    Wu, M.2    Sanchez, M.3    Stein, P.4
  • 25
    • 33846817233 scopus 로고    scopus 로고
    • Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: A randomized, double-blind, non-inferiority trial
    • Nauck MA, Meininger JG, Sheng D, Terranella L, Stein PP. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial. Diabetes Obes Metab 2007; 9:194-205.
    • (2007) Diabetes Obes Metab , vol.9 , pp. 194-205
    • Nauck, M.A.1    Meininger, J.G.2    Sheng, D.3    Terranella, L.4    Stein, P.P.5
  • 26
    • 85036946660 scopus 로고    scopus 로고
    • Scott RS, Hartley P, Luo E, et al. Use of sitagliptin in patients with type 2 diabetes and renal insufficiency [abtract]. Diabetes 2006; 55(suppi 1):A462.
    • Scott RS, Hartley P, Luo E, et al. Use of sitagliptin in patients with type 2 diabetes and renal insufficiency [abtract]. Diabetes 2006; 55(suppi 1):A462.
  • 27
    • 84882255983 scopus 로고    scopus 로고
    • Last accessed February 28, 2008
    • Januvia prescribing information. www.merck.com/product/usa/ pi_circulars/j/products_j.html. Last accessed February 28, 2008.
    • Januvia prescribing information
  • 28
    • 27744540889 scopus 로고    scopus 로고
    • Improved glycaemic control with dipeptidyl-peptidase-4 inhibition in patients with type 2 diabetes: Vildagliptin (LAF237) dose response
    • Ristic S, Byiers S, Foley J, Holmes D. Improved glycaemic control with dipeptidyl-peptidase-4 inhibition in patients with type 2 diabetes: vildagliptin (LAF237) dose response. Diabetes Obes Metab 2005; 7:692-698.
    • (2005) Diabetes Obes Metab , vol.7 , pp. 692-698
    • Ristic, S.1    Byiers, S.2    Foley, J.3    Holmes, D.4
  • 30
    • 9444285818 scopus 로고    scopus 로고
    • Twelve- and 52-week efficacy of the dipeptidyl peptidase iv inhibitor laf237 in metformin-treated patients with type 2 diabetes
    • Ahrén B, Gomis R, Standl E, Mills D, Schweizer A. Twelve- and 52-week efficacy of the dipeptidyl peptidase iv inhibitor laf237 in metformin-treated patients with type 2 diabetes. Diabetes Care 2004; 27:2874-2880.
    • (2004) Diabetes Care , vol.27 , pp. 2874-2880
    • Ahrén, B.1    Gomis, R.2    Standl, E.3    Mills, D.4    Schweizer, A.5
  • 31
    • 34147093268 scopus 로고    scopus 로고
    • Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin
    • Bosi E, Camisasca RP, Collober C, Rochotte E, Garber AJ. Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin. Diabetes Care 2007; 30:890-895.
    • (2007) Diabetes Care , vol.30 , pp. 890-895
    • Bosi, E.1    Camisasca, R.P.2    Collober, C.3    Rochotte, E.4    Garber, A.J.5
  • 32
    • 33846828660 scopus 로고    scopus 로고
    • Vildagliptin in combination with pioglitazone improves glycaemic control in patients with type 2 diabetes failing thiazolidinedione monotherapy: A randomized, placebo-controlled study
    • Garber A, Schweizer A, Baron MA, Rochotte E, Dejager S. Vildagliptin in combination with pioglitazone improves glycaemic control in patients with type 2 diabetes failing thiazolidinedione monotherapy: a randomized, placebo-controlled study. Diabetes Obes Metab 2007; 9:166-174.
    • (2007) Diabetes Obes Metab , vol.9 , pp. 166-174
    • Garber, A.1    Schweizer, A.2    Baron, M.A.3    Rochotte, E.4    Dejager, S.5
  • 33
  • 34
    • 33748316958 scopus 로고    scopus 로고
    • Sustained reduction in HbA1c during one-year treatment with vildagliptin in patients with type 2 diabetes (T2DM) [abstract]
    • Dejager S, LeBeaut A, Couturier A, Schweizer A. Sustained reduction in HbA1c during one-year treatment with vildagliptin in patients with type 2 diabetes (T2DM) [abstract]. Diabetes 2006; 55(suppl 1):A29.
    • (2006) Diabetes , vol.55 , Issue.SUPPL. 1
    • Dejager, S.1    LeBeaut, A.2    Couturier, A.3    Schweizer, A.4
  • 35
    • 33846694046 scopus 로고    scopus 로고
    • Comparison of vildagliptin and rosiglitazone monotherapy in patients with type 2 diabetes
    • Rosenstock J, Baron MA, Dejager S, Mills D, Schweizer A. Comparison of vildagliptin and rosiglitazone monotherapy in patients with type 2 diabetes. Diabetes Care 2007; 30:217-223.
    • (2007) Diabetes Care , vol.30 , pp. 217-223
    • Rosenstock, J.1    Baron, M.A.2    Dejager, S.3    Mills, D.4    Schweizer, A.5
  • 36
    • 33846827085 scopus 로고    scopus 로고
    • Efficacy and tolerability of initial combination therapy with vildagliptin and pioglitazone compared with component monotherapy in patients with type 2 diabetes
    • Rosenstock J, Baron MA, Camisasca R-P, Cressier F, Couturier A, Dejager S. Efficacy and tolerability of initial combination therapy with vildagliptin and pioglitazone compared with component monotherapy in patients with type 2 diabetes. Diabetes Obes Metab 2007; 9:175-185.
    • (2007) Diabetes Obes Metab , vol.9 , pp. 175-185
    • Rosenstock, J.1    Baron, M.A.2    Camisasca, R.-P.3    Cressier, F.4    Couturier, A.5    Dejager, S.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.